ASTRO: Is hormone therapy after prostate surgery needed?

CHICAGO - Men who have undergone surgery for prostate cancer may not need long-term...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA PET/MRI, mpMRI work for prostate cancer analysis AI, radiomics predict prostate cancer aggressiveness NaF-PET/CT does well in detecting prostate metastases NaF-PET/CT rarely finds prostate cancer bone metastases Could Ga-68 PSMA PET become essential for prostate cancer?
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Publication date: Available online 9 October 2019Source: The Journal of Molecular DiagnosticsAuthor(s): Andrea J. Savio, Shivani Kamdar, Renu Jeyapala, Ekaterina Olkhov-Mitsel, Carmelle Cuizon, Antonio Finelli, Alexandre R. Zlotta, Ants Toi, Neil E. Fleshner, Theodorus van der Kwast, Bharati BapatAbstractAfter diagnosis of prostate cancer is confirmed by a positive biopsy, the tumor may be surgically removed via radical prostatectomy (RP). However, many prostate cancer patients experience biochemical recurrence post-surgery and/or undergo salvage radiotherapy or hormone therapy. Timely treatment is required to prevent the ...
Source: The Journal of Molecular Diagnostics - Category: Pathology Source Type: research
Men with advanced prostate cancer who stop responding to targeted hormone therapy but are then treated with modern chemotherapy have better survival rates than those given a second targeted treatment, a study published in the New England Journal of Medicine has shown.
Source: The Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Results presented at the European Society for Medical Oncology Congress 2019 reveal that breast and ovarian cancer drugs are more effective at treating prostate cancer, than targeted hormone therapy.News Medical
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
ConclusionsSCCs are enriched for 11q13+ with preliminary evidence for linking them to HPV- status. The co-occurrence of 11q13+ with both ESR1 and AR mutations suggests a co-operative role in acquired resistance to hormonal therapy, but not to TKIs. Further investigation will be 11q13+ in the development of SCC and acquired resistance to hormonal therapies appears warranted.Legal entity responsible for the studyFoundation Medicine.FundingFoundation Medicine.DisclosureJ.Johnson: Consultant: Foundation Medicine Consultant: Rakuten-Aspyrian. J. Lee: Full / Part-time employment: Foundation Medicine; Shareholder / Stockholder / ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundAbiraterone and enzalutamide represent the standard treatment in castration resistance prostate cancer (CRPC) patients, however, some patient displays primary resistance, and several studies investigated the role of the androgen receptor (AR) as a predictive biomarker of response to treatment (Conteduca, et al. Ann Oncol. 2017;28(7):1508-1516; Del Re, et al. BJU Int. 2019 doi: 10.1111/bju.14792). The present study is aimed at evaluating the role the AR in liquid biopsy to predict response to hormone treatment in CRPC patients.MethodsSix ml of plasma samples were collected from patients affected by castrat...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ASK THE GP: After a prostate cancer diagnosis at 69, I had hormone therapy and radiotherapy. A year later, I'm still suffering intense and frequent hot flushes- 20 to 25 a day. What can I do?
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Abstract PURPOSE: Patients with clinically localized, high-risk prostate cancer are often treated with surgery, but exhibit variable prognosis requiring long-term monitoring. An ongoing challenge for such patients is developing optimal strategies and biomarkers capable of differentiating between men at risk of early recurrence (5 years) who will benefit from long-term monitoring and/or salvage therapies. PATIENTS AND METHODS: DNA methylation changes for 12 genes associated with disease progression were analyzed in 453 prostate tumors. A 4-gene prognostic model (4-G model) for biochemical recurrence (BCR) was ...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
Treatments for advanced prostate cancer that suppress testosterone, a hormone (also called an androgen) that drives the malignant cells to grow and spread, are collectively referred to as androgen deprivation therapies, or ADT. These therapies can significantly extend lifespans in men who have the disease, but they also have a range of challenging side effects. In 2004, Dr. Marc Garnick, Gorman Brothers Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center, and editor in chief of HarvardProstateKnowledge.org, reported that in some men, an ADT drug called aberelix lengthens the time it tak...
Source: Harvard Health Blog - Category: Consumer Health News Authors: Tags: Health Living With Prostate Cancer Men's Health Prostate Health Prostate Knowledge Treatments HPK Source Type: blogs
Patients with non-Hodgkin's lymphoma who received radiation 30 days or less...Read more on AuntMinnie.comRelated Reading: ASTRO: AI predicts side effects from radiation therapy ASTRO: Is hormone therapy after prostate surgery needed? ASTRO: SABR generates immune response to prostate cancer ASTRO: Cervical cancer deaths rise as women's centers close ASTRO: Whole, partial breast RT yield similar cosmetic results
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Just one high dose of radiation to the heart can significantly reduce episodes...Read more on AuntMinnie.comRelated Reading: ASTRO: AI predicts side effects from radiation therapy ASTRO: Is hormone therapy after prostate surgery needed? ASTRO: SABR generates immune response to prostate cancer ASTRO: Cervical cancer deaths rise as women's centers close ASTRO: Whole, partial breast RT yield similar cosmetic results
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
More News: Cancer | Cancer & Oncology | Hormonal Therapy | Hormones | Prostate Cancer | Radiology